Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Cellectis SA ( (CLLS) ) is now available.
Cellectis S.A., a clinical-stage biotechnology company specializing in gene-edited, off-the-shelf CAR T-cell therapies and other cell and gene therapies, operates an end-to-end platform with in-house manufacturing across sites in Paris, New York and Raleigh. The group targets oncology and broader genetic indications, leveraging listings on Nasdaq and Euronext Growth to access international capital markets.
On March 12, 2026, Cellectis announced it will release its fourth-quarter and full-year 2025 financial results, covering the period ended December 31, 2025, after the U.S. market close on March 19, 2026. The company will follow the publication with an investor conference call and webcast on March 20, 2026, where it plans to discuss those results and provide an update on its business activities, signaling upcoming visibility for investors into its financial performance and strategic progress.
The most recent analyst rating on (CLLS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is primarily influenced by its strong technical indicators, which suggest positive market momentum. However, the company’s financial performance and valuation are concerning due to persistent unprofitability and negative cash flow, which significantly impact the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company that uses a proprietary gene-editing platform to develop life-saving cell and gene therapies. The company focuses on allogeneic, off-the-shelf CAR T immunotherapies for oncology and is also building gene therapies for other indications, supported by in-house manufacturing that gives it end-to-end control of the value chain.
Headquartered in Paris with additional sites in New York and Raleigh, N.C., Cellectis is listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS. Its positioning as an integrated gene-editing player aims to address global demand for scalable, ready-to-use cell and gene therapies.
Average Trading Volume: 57,608
Technical Sentiment Signal: Hold
Current Market Cap: $281.6M
See more data about CLLS stock on TipRanks’ Stock Analysis page.